216 related articles for article (PubMed ID: 8630428)
1. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.
Lucas KG; Small TN; Heller G; Dupont B; O'Reilly RJ
Blood; 1996 Mar; 87(6):2594-603. PubMed ID: 8630428
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy for Epstein-Barr virus-related lymphoma.
Smith CA; Ng CY; Loftin SK; Li C; Heslop HE; Brenner MK; Rooney CM
Leuk Lymphoma; 1996 Oct; 23(3-4):213-20. PubMed ID: 9031101
[TBL] [Abstract][Full Text] [Related]
4. Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants.
O'Reilly RJ; Lacerda JF; Lucas KG; Rosenfield NS; Small TN; Papadopoulos EB
Important Adv Oncol; 1996; ():149-66. PubMed ID: 8791134
[No Abstract] [Full Text] [Related]
5. Virus-specific cytotoxic T lymphocytes as prophylaxis for Epstein-Barr virus lymphoproliferative disease in pediatric bone marrow transplant recipients.
Norville R; Nance D; Cheshire S
J Pediatr Oncol Nurs; 1997 Oct; 14(4):194-201. PubMed ID: 9322393
[TBL] [Abstract][Full Text] [Related]
6. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation.
Lucas KG; Burton RL; Zimmerman SE; Wang J; Cornetta KG; Robertson KA; Lee CH; Emanuel DJ
Blood; 1998 May; 91(10):3654-61. PubMed ID: 9573001
[TBL] [Abstract][Full Text] [Related]
7. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for Epstein-Barr virus-associated cancers.
Rooney CM; Roskrow MA; Smith CA; Brenner MK; Heslop HE
J Natl Cancer Inst Monogr; 1998; (23):89-93. PubMed ID: 9709309
[TBL] [Abstract][Full Text] [Related]
9. Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD).
Imashuku S; Goto T; Matsumura T; Naya M; Yamori M; Hojo M; Hibi S; Todo S
Bone Marrow Transplant; 1997 Aug; 20(4):337-40. PubMed ID: 9285550
[TBL] [Abstract][Full Text] [Related]
10. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.
Rooney CM; Smith CA; Ng CY; Loftin SK; Sixbey JW; Gan Y; Srivastava DK; Bowman LC; Krance RA; Brenner MK; Heslop HE
Blood; 1998 Sep; 92(5):1549-55. PubMed ID: 9716582
[TBL] [Abstract][Full Text] [Related]
11. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
[TBL] [Abstract][Full Text] [Related]
13. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.
Smith CA; Ng CY; Heslop HE; Holladay MS; Richardson S; Turner EV; Loftin SK; Li C; Brenner MK; Rooney CM
J Hematother; 1995 Apr; 4(2):73-9. PubMed ID: 7633844
[TBL] [Abstract][Full Text] [Related]
14. Fatal B-cell lymphoproliferative syndrome in allogeneic marrow graft recipients. A clinical, immunobiological and pathological study.
Simon M; Bartram CR; Friedrich W; Arnold R; Schmeiser T; Hampl W; Müller-Hermelink HK; Heymer B
Virchows Arch B Cell Pathol Incl Mol Pathol; 1991; 60(5):307-19. PubMed ID: 1685038
[TBL] [Abstract][Full Text] [Related]
15. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes.
Emanuel DJ; Lucas KG; Mallory GB; Edwards-Brown MK; Pollok KE; Conrad PD; Robertson KA; Smith FO
Transplantation; 1997 Jun; 63(11):1691-4. PubMed ID: 9197369
[TBL] [Abstract][Full Text] [Related]
16. Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection.
Kuzushima K; Yamamoto M; Kimura H; Ando Y; Kudo T; Tsuge I; Morishima T
Clin Exp Immunol; 1996 Feb; 103(2):192-8. PubMed ID: 8565299
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.
van Esser JW; van der Holt B; Meijer E; Niesters HG; Trenschel R; Thijsen SF; van Loon AM; Frassoni F; Bacigalupo A; Schaefer UW; Osterhaus AD; Gratama JW; Löwenberg B; Verdonck LF; Cornelissen JJ
Blood; 2001 Aug; 98(4):972-8. PubMed ID: 11493441
[TBL] [Abstract][Full Text] [Related]
18. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
Sun Q; Burton R; Reddy V; Lucas KG
Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
[TBL] [Abstract][Full Text] [Related]
19. Serological and molecular studies of Epstein-Barr virus infection in allogeneic marrow graft recipients.
Gratama JW; Oosterveer MA; Lepoutre JM; van Rood JJ; Zwaan FE; Vossen JM; Kapsenberg JG; Richel D; Klein G; Ernberg I
Transplantation; 1990 Apr; 49(4):725-30. PubMed ID: 2158159
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation.
Chiang KY; Hazlett LJ; Godder KT; Abhyankar SH; Christiansen NP; van Rhee F; Lee CG; Bridges K; Parrish RS; Henslee-Downey PJ
Bone Marrow Transplant; 2001 Dec; 28(12):1117-23. PubMed ID: 11803352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]